BioSyent Pharma Signs License, Supply and Distribution AgreementBioSyent Inc. ("BioSyent") (TSX VENTURE: RX) announces that its subsidiary BioSyent Pharma Inc. has signed an agreement with a new partner for a new product under its Hospital Products Division. The product will be launched after Health Canada approval.

BioSyent Inc. continues to concentrate on its pharmaceutical strategy to source products that have been successfully developed and proven to be safe and effective; manage these products through the regulatory process and product registration (approval); and once approved, market these products in Canada. These pharmaceuticals will compete in both the branded and generic market segments and will not require further product development investment other than regulatory costs.